CLMT:NGS-Calumet Specialty Products Partners L.P. (USD)

EQUITY | Specialty Chemicals | Nasdaq Global Select

Last Closing

USD 9.22

Change

-0.54 (-5.53)%

Market Cap

USD 0.35B

Volume

0.62M

Analyst Target

USD 3.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Calumet Specialty Products Partners LP is a producer of hydrocarbon products in North America. It owns specialty and fuel products facilities located in northwest Louisiana, northwest Wisconsin, northern Montana, Texas, New Jersey, and other areas.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap
LIN Linde plc Ordinary Shares

+10.76 (+2.42%)

USD 208.95B
BCPC Balchem Corporation

+0.58 (+0.37%)

USD 5.33B
WDFC WD-40 Company

+5.07 (+2.31%)

USD 3.12B
HWKN Hawkins Inc

+2.93 (+2.44%)

USD 2.21B
IOSP Innospec Inc

+1.74 (+2.01%)

USD 2.16B
GEVO Gevo Inc

+0.07 (+6.25%)

USD 0.32B
HDSN Hudson Technologies Inc

+0.03 (+0.57%)

USD 0.24B
LWLG Lightwave Logic Inc

+0.05 (+6.32%)

USD 0.13B
NTIC Northern Technologies

+0.25 (+3.65%)

USD 0.11B
ALTO Alto Ingredients Inc

+0.02 (+2.41%)

USD 0.09B

ETFs Containing CLMT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Specialty Chemicals) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -58.13% 26% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.13% 26% F 10% F
Trailing 12 Months  
Capital Gain -39.99% 63% D 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.99% 63% D 28% F
Trailing 5 Years  
Capital Gain 494.84% 83% B 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 494.84% 83% B 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 73.00% 79% B- 92% A
Dividend Return 73.00% 79% B- 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 98.07% 32% F 20% F
Risk Adjusted Return 74.43% 84% B 90% A-
Market Capitalization 0.35B 72% C 71% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Specialty Chemicals) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.07 38% 34%
Price/Book Ratio 19.32 6% 7%
Price / Cash Flow Ratio -18.11 94% 90%
Price/Free Cash Flow Ratio 19.11 29% 18%
Management Effectiveness  
Return on Equity -1,172.22% 6% 3%
Return on Invested Capital 0.52% 47% 58%
Return on Assets 1.76% 59% 71%
Debt to Equity Ratio -290.03% 100% 96%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector